Citigroup Downgrades Krystal Biotech to Neutral, Raises Price Target to $204
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Yigal Nochomovitz has downgraded Krystal Biotech (NASDAQ:KRYS) from Buy to Neutral while raising the price target from $195 to $204.

August 06, 2024 | 12:17 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Citigroup analyst Yigal Nochomovitz downgraded Krystal Biotech from Buy to Neutral, but raised the price target from $195 to $204.
The downgrade from Buy to Neutral suggests a less optimistic outlook on the stock's performance, which could lead to a neutral or slightly negative short-term impact. However, the raised price target to $204 indicates some underlying positive factors, balancing the overall impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100